^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)

    i
    Associations
    News

    Trials

    Company:
    Guangzhou Trinomab Biotechnology
    Drug class:
    Dendritic cell activator
    Related drugs:
    Associations
    News

    Trials

    Apply
    Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC) (NCT02709616)
    Phase 1
    Guangdong 999 Brain Hospital
    Completed
    Last update posted :
    05/27/2022
    Initiation :
    03/01/2016
    Primary completion :
    10/31/2017
    Completion :
    06/30/2019
    CD4
    |
    tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)
    Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2) (PerCellVac2) (NCT02808364)
    Phase 1
    Guangdong 999 Brain Hospital
    Completed
    Last update posted :
    05/27/2022
    Initiation :
    03/01/2016
    Primary completion :
    10/31/2017
    Completion :
    06/30/2019
    CD4
    |
    tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)
    Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) (PerCellVac3) (NCT02808416)
    Phase 1
    Guangdong 999 Brain Hospital
    Completed
    Last update posted :
    05/27/2022
    Initiation :
    03/01/2016
    Primary completion :
    10/31/2017
    Completion :
    06/30/2019
    CD4
    |
    tumor antigen pulsed DC autologous cellular vaccine (personalized cellular vaccine)